5JUL

WHO lists first Bundibugyo Ebola test

2 min read

10:12UTC

WHO added the first molecular test for Bundibugyo virus to its Emergency Use Listing on 2 July, as testing across the affected provinces climbed past 2,000 samples a day.

← Back to Ebola's toolkit arrives, outbreak climbs Jump to analysis ↓

ScienceDeveloping

Key takeaway

WHO listed the first Bundibugyo-specific diagnostic on 2 July as regional testing passed 2,000 samples a day.

WHO added the first molecular diagnostic for Bundibugyo virus (BDBV) to its Emergency Use Listing (EUL) on Thursday 2 July, the regulatory route that lets an unlicensed product be used in a crisis once WHO has vetted its quality and performance⁠¹. No BDBV-specific test had ever been listed before. The test reads the virus's genetic material from a blood sample, and its listing matters because every unconfirmed suspected case is a person WHO might be infectious and untraced.

Testing capacity across the affected provinces has risen from roughly 200 to 400 tests a day at two facilities to more than 2,000 a day across a network of ten laboratories. "Timely access to quality-assured diagnostic tests can make a critical difference in containing transmission," said Dr Yukiko Nakatani, a WHO assistant director-general. The manufacturer was not named in the release.

WHO had to clear a testing backlog in June and recalibrate to confirmed-only reporting, so faster confirmation now closes a gap that had repeatedly made the outbreak's own headline count lurch rather than climb cleanly. The WHO R&D Blueprint, the programme that names priority pathogens, had flagged the missing Bundibugyo diagnostic as a gap in March, three months before the outbreak surfaced; that gap is now partly closed.

Deep Analysis

In plain English

A molecular diagnostic test looks for the virus's genetic material directly in a blood sample, which is faster and more specific than tests that look for antibodies the body makes later. Until 2 July, DRC labs testing for Bundibugyo ebolavirus relied on general-purpose Ebola tests not built for this specific strain, or had to send samples to a handful of central labs, causing delays. WHO's Emergency Use Listing is a fast-track approval process for tools urgently needed during an outbreak, used when there isn't time to wait for the years-long standard review. It let ten labs start using the new test immediately, pushing daily testing capacity from under 400 to over 2,000.

Deep Analysis

Root Causes

Point-of-care diagnostics for rare pathogens like Bundibugyo ebolavirus sit in what diagnostics developers call the valley of death: a manufacturer can recoup clinical-validation and EUL-submission costs only if a large, predictable market follows, and an outbreak-limited disease offers no such market once the emergency ends.

PATH and similar non-profit intermediaries typically bridge that gap by pre-negotiating volume guarantees, which is why WHO's Emergency Use Listing route exists at all: full prequalification review, built for commercial-scale products, cannot move fast enough for an active outbreak.

A test built specifically for Bundibugyo virus would also have flagged the French returnee case faster than the general Ebola serology assay used to confirm it in late June, since a species-specific PCR target returns a positive result before antibodies appear.

Source Landscape

This story draws on neutral-leaning sources from Switzerland

Switzerland

Primary parallel: The US Centers for Disease Control and Prevention secured emergency-use authorisation for its H1N1 real-time PCR test within four weeks of the 2009 pandemic being declared, showing how an emergency pathway can compress a multi-year validation process into weeks when political will and funding align.

Counter-parallel: During the 2022 mpox emergency, non-variola orthopoxvirus PCR testing stayed confined to a handful of reference laboratories for several months, since biosafety-level requirements for handling the specimens blocked the decentralised rollout that BDBV testing achieved in ten DRC sites within weeks.

Consensus view: FIND, the Foundation for Innovative New Diagnostics, rates the Emergency Use Listing as the mechanism that let ten DRC laboratories move from screening a few hundred samples a day to over 2,000, since EUL status let local labs import the assay without waiting for full WHO prequalification, a process that typically takes years.

Counter-view: The Africa Society for Laboratory Medicine counters that listing alone does not solve the cartridge cost and cold-chain gap; each of the ten labs still needs continuous 2-8°C storage and a steady cartridge supply that a DRC health budget cannot sustain once outbreak-response funding tapers off.

Key tension: Whether the ten-laboratory network built for this outbreak survives as permanent testing capacity or reverts to two facilities once the emergency listing's associated funding ends.

Sources:WHO

Mentions:Bundibugyo ebolavirus →WHO R&D Blueprint →DR Congo →Emergency Use Listing →World Health Organization →

First Reported In

Update #9 · Ebola's toolkit arrives, outbreak climbs

WHO· 5 Jul 2026

Read original →

Different Perspectives

IGWG co-chair Tovar da Silva Nunes

The Brazilian co-chair closed the eighth pathogen-sharing session on 18 September without an agreed annex text, the second session in a row to end that way. He presented the outcome as continued commitment, with adoption due at the World Health Assembly in May 2027.

Fraport

The Frankfurt Airport operator has told staff to watch for fever, hessenschau reported, after six airport workers caught malaria. Germany does not require insecticide spraying of arriving aircraft cabins, and parasite genotyping to trace the source is due at the end of October.

European Centre for Disease Prevention and Control

ECDC reported the eight Frankfurt Airport malaria cases on 18 September and considers repeated arrivals of infected mosquitoes on aircraft likely. It has not ruled out local mosquitoes, and awaits genotyping due at the end of October.

Pan American Health Organization

PAHO counted 53,957 measles cases in the Americas by 19 September and is supporting Peru's response in Puno and Arequipa. It warns that October's Señor de los Milagros festivities and Pope Leo XIV's November visit could increase transmission.

Bangladesh Directorate General of Health Services

The DGHS recorded 1,030 measles-related deaths and 172,720 suspected cases by 14 September, after a campaign that reached 19.75 million children. Its disease-control director, Halimur Rashid, said further vaccination rounds were expected within two weeks.

Minapharm

The Egyptian drugmaker and its Berlin subsidiary ProBioGen were awarded up to US$16.5m by CEPI on 27 August to take a Bundibugyo vaccine into a Phase 1 trial in Africa. Final manufacture is planned for Cairo, making it CEPI's first Bundibugyo candidate with an African producer.